Drug intelligence / Profile preview

KRP-A218

Development stage: Phase 1
Lead developer: Kyorin Pharmaceutical
Administration: Oral

Overview

KRP-A218 is a drug developed by Kyorin Pharmaceutical Co.,Ltd. currently undergoing a first-in-human, Phase I clinical trial. This study is a double-blind, placebo-controlled, single and multiple ascending oral dose study designed to evaluate the safety, tolerability, and pharmacokinetics of KRP-A218 in healthy subjects. The trial also includes an assessment of food-effect and potential drug-drug interactions with itraconazole.

Targets

PI4KB (Phosphatidylinositol 4-kinase beta)

Beyond the preview

Go deeper on KRP-A218.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KRP-A218.

Explore the full profile